Form 4: 10x Genomics Officer Sells Shares for Tax Obligations
Insider Transaction Report
10x Genomics President and Chief Scientific Officer, Benjamin J. Hindson, sold 7,826 shares of Class A Common Stock to cover tax withholding obligations.
Summary
- Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (TXG), disposed of 7,826 shares of Class A Common Stock.
- The transaction occurred on February 23, 2026, at a price of $18.5764 per share.
- The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units.
- Following this transaction, Benjamin J. Hindson beneficially owns 424,779 shares of Class A Common Stock.
- A Power of Attorney, dated February 24, 2026, appoints Randy Wu and James Bryant to handle SEC filings on behalf of Benjamin Hindson.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and tax planning, and not reflective of a change in the company's operational performance or outlook.
Future Outlook
No specific forward-looking statements or guidance are provided in this insider transaction report.
Management Comments
- The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
Industry Context
StockSavvy.ai notes that insider sales for tax purposes, such as those related to the vesting of restricted stock units, are a common and routine occurrence in the biotechnology and life sciences industry. These transactions are generally not indicative of a change in an executive's sentiment regarding the company's long-term prospects or operational performance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Administrative Update | A Power of Attorney was executed, appointing Randy Wu and James Bryant as attorneys-in-fact to prepare and file Forms 3, 4, and 5 with the SEC on behalf of Benjamin Hindson. | 02/24/2026 | This streamlines the process for insider trading compliance filings, ensuring timely and accurate reporting for the executive. |
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, tax-related transaction and not a discretionary sale based on new information.
Key Dates
| Date | Description |
|---|---|
| 02/24/2026 | Date of execution for the Power of Attorney document. |
| 02/23/2026 | Date of the reported transaction where shares were sold. |
| 02/25/2026 | Date the Form 4 was signed by the attorney-in-fact. |
Recommendation
holdThe reported transaction is a routine sale of shares by an insider to cover tax obligations associated with the vesting of restricted stock units. Such transactions are common and generally do not indicate a change in the company's fundamental prospects or the insider's long-term view of the stock. Therefore, a 'hold' recommendation is appropriate as this event alone does not provide new information to alter an existing investment thesis.
Keywords
10x Genomics, TXG, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Benjamin Hindson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.